U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT06795022) titled 'First in Human Study to Evaluate AZD9793 in Participants With Advanced or Metastatic Solid Tumours' on Jan. 08.
Brief Summary: This research is designed to determine if experimental treatment with AZD9793, a T cell-engaging antibody that targets GPC3, is safe, tolerable and has anti-cancer activity in patients with advanced or metastatic solid tumours which are GPC3+.
Study Start Date: Feb. 27
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Carcinoma
Intervention:
DRUG: AZD9793 Intravenous (IV) monotherapy
T cell-engaging antibody that targets GPC3 on tumour cells
DRUG: AZD9793 Subcutaneous (SC) monotherapy)
T cell-eng...